STAT3 and ovarian carcinoma: In animal models, targeting STAT3 in combination with paclitaxel can synergistically reduce intraperitoneal dissemination and prolong the survival of mice with ovarian cancer (Chen M. W. et al., 2017; Park and Kim, 2019).